Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
NEWARK, Calif., May 02, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2017 financial results on Tuesday, May 9, 2017, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
Participants can access the call by dialing (844) 839-0046 (United States) or (857) 270-6032 (International) referencing Conference ID 10761035. The conference call will also be available via a live webcast on the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
